Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 355-363

  Kadota, Kyuichi ^a   Huang, Cheng Long ^a   Liu, Dage ^a   Yokomise, Hiroyaseu ^a   Haba, Reiji ^a   Wada, Hiromi ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

5 FU; Gene therapy; S 1; shRNA; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ADENOVIRUS VECTOR; FLUOROURACIL; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CARCINOMA; DRUG RESISTANCE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; OXONIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TEGAFUR; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651233358     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.880     Document Type: Article

References (39)

1. Huang C, Liu D, Masuya D, et al: Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92: 1231-1239, 2005.
2. Huang C, Yokomise H, Fukushima M and Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2: 289-299, 2006.
3. Takiuchi H and Ajani JA: Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 16: 2877-2885, 1998.
4. Macdonald JS and Astrow AB: Adjuvant therapy of colon cancer. Semin Oncol 28: 30-40, 2001.
5. Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan study group for lung cancer surgery. J Clin Oncol 14: 1048-1054, 1996.
6. Rustum YM, Harstrick A, Cao S, et al: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389-400, 1997.
7. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522, 1994.
8. Nakano J, Huang C, Liu D, et al: Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 95: 607-615, 2006.
9. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
10. Yeh KH, Shun CT, Chen CL, et al: High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626-1631, 1998.
11. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005.
12. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
13. Huang C, Li M, Chen C and Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 12: 637-645, 2008.
14. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
15. Rao DD, Vorhies JS, Senzer N and Nemunaitis J: siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61: 746-759, 2009.
16. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063-1069, 2009.
17. Yoshioka T, Kato S, Gamoh M, et al: Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 101: 1972-1977, 2009.
18. Ohyanagi F, Yamamoto N, Horiike A, et al: Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101: 225-231, 2009.
19. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N and Fukushima M: Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 17: 277-283, 2000.
20. Inaba M, Mitsuhashi J, Sawada H, et al: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 87: 212-220, 1996.
21. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001.
22. Kanegae Y, Makimura M and Saito I: A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 47: 157-166, 1994.
23. Takechi T, Uchida J, Fujioka A and Fukushima M: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11: 1041-1044, 1997.
24. Navalgund LG, Rossana C, Muench, AJ and Johnson LF: Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 255: 7386-7390, 1980.
25. Derenzini M, Montanaro L, Trere D, et al: Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol Pathol 55: 310-314, 2002.
26. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC and Bertino JR: Role of E2F-1 in chemosensitivity. Cancer Res 58: 4292-4296, 1998.
27. Sui G, Soohoo C, Affar el B, et al: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520, 2002.
28. Anderson WF: Human gene therapy. Nature 392: 25-30, 1998.
29. Vile R: Cancer gene therapy-new approaches to tumour cell killing. J Gene Med 2: 141-143, 2000.
30. Keedy V, Wang W, Schiller J, et al: Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 26: 4166-4171, 2008.
31. Rahman L, Voeller D, Rahman M, et al: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
32. Hashimoto H, Ozeki Y, Sato M, et al: Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 106: 1595-1601, 2006.
33. Tsujitani S, Konishi I, Suzuki K, et al: Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin Cancer Res 19: 189-195, 2000.
34. Edler D, Kressner U, Ragnhammar P, et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6: 488-492, 2000.
35. Romain S, Spyratos F, Descotes F, et al: Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synathase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. Int J Cancer 87: 860-868, 2000.
36. Schmitz JC, Chen T and Chu E: Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 64: 1431-1435, 2004.
37. Fischel JL, Etienne MC, Spector T, Formento P, Renee N and Milano G: Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1: 991-996, 1995.
38. Ma B, Zhang S, Jiang H, Zhao B and Lv H: Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release 123: 184-194, 2007.
39. Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318-1325, 2004.